These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32538781)

  • 1. HIV-1 Vpr induces cell cycle arrest and enhances viral gene expression by depleting CCDC137.
    Zhang F; Bieniasz PD
    Elife; 2020 Jun; 9():. PubMed ID: 32538781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions with DCAF1 and DDB1 in the CRL4 E3 ubiquitin ligase are required for Vpr-mediated G2 arrest.
    Hakata Y; Miyazawa M; Landau NR
    Virol J; 2014 Jun; 11():108. PubMed ID: 24912982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV-1 Vpr-induced DNA damage activates NF-κB through ATM-NEMO independent of cell cycle arrest.
    Sandoval C; Nisson K; Fregoso OI
    mBio; 2024 Oct; 15(10):e0024024. PubMed ID: 39269169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the interactions and role of DCAF1/VPRBP in the DDB1-cullin4A E3 ubiquitin ligase complex engaged by HIV-1 Vpr to induce a G2 cell cycle arrest.
    Gérard FC; Yang R; Romani B; Poisson A; Belzile JP; Rougeau N; Cohen ÉA
    PLoS One; 2014; 9(2):e89195. PubMed ID: 24558487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Vpr Protein Enhances Proteasomal Degradation of MCM10 DNA Replication Factor through the Cul4-DDB1[VprBP] E3 Ubiquitin Ligase to Induce G2/M Cell Cycle Arrest.
    Romani B; Shaykh Baygloo N; Aghasadeghi MR; Allahbakhshi E
    J Biol Chem; 2015 Jul; 290(28):17380-9. PubMed ID: 26032416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The HIV1 protein Vpr acts to enhance constitutive DCAF1-dependent UNG2 turnover.
    Wen X; Casey Klockow L; Nekorchuk M; Sharifi HJ; de Noronha CM
    PLoS One; 2012; 7(1):e30939. PubMed ID: 22292079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 Vpr hijacks EDD-DYRK2-DDB1
    Hossain D; Ferreira Barbosa JA; Cohen ÉA; Tsang WY
    J Biol Chem; 2018 Jun; 293(24):9448-9460. PubMed ID: 29724823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human Immunodeficiency Virus Type 1 Vpr Mediates Degradation of APC1, a Scaffolding Component of the Anaphase-Promoting Complex/Cyclosome.
    Barbosa JAF; Sparapani S; Boulais J; Lodge R; Cohen ÉA
    J Virol; 2021 Jul; 95(15):e0097120. PubMed ID: 34011540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase.
    Belzile JP; Duisit G; Rougeau N; Mercier J; Finzi A; Cohen EA
    PLoS Pathog; 2007 Jul; 3(7):e85. PubMed ID: 17630831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Vpx-Mediated SAMHD1 and Vpr-Mediated Host Helicase Transcription Factor Degradation by Selective Disruption of Viral CRL4 (DCAF1) E3 Ubiquitin Ligase Assembly.
    Wang H; Guo H; Su J; Rui Y; Zheng W; Gao W; Zhang W; Li Z; Liu G; Markham RB; Wei W; Yu XF
    J Virol; 2017 May; 91(9):. PubMed ID: 28202763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assembly with the Cul4A-DDB1DCAF1 ubiquitin ligase protects HIV-1 Vpr from proteasomal degradation.
    Le Rouzic E; Morel M; Ayinde D; Belaïdouni N; Letienne J; Transy C; Margottin-Goguet F
    J Biol Chem; 2008 Aug; 283(31):21686-92. PubMed ID: 18524771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of NKG2D-mediated cytotoxic functions of natural killer cells by viral protein R from HIV-1 primary isolates.
    Pham TN; Richard J; Gerard FC; Power C; Cohen ÉA
    J Virol; 2011 Dec; 85(23):12254-61. PubMed ID: 21957298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virion-Associated Vpr Alleviates a Postintegration Block to HIV-1 Infection of Dendritic Cells.
    Miller CM; Akiyama H; Agosto LM; Emery A; Ettinger CR; Swanstrom RI; Henderson AJ; Gummuluru S
    J Virol; 2017 Jul; 91(13):. PubMed ID: 28424288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 Accessory Protein Vpr Interacts with REAF/RPRD2 To Mitigate Its Antiviral Activity.
    Gibbons JM; Marno KM; Pike R; Lee WJ; Jones CE; Ogunkolade BW; Pardieu C; Bryan A; Fu RM; Warnes G; Rowley PA; Sloan RD; McKnight Á
    J Virol; 2020 Jan; 94(4):. PubMed ID: 31776272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for Vpr-dependent HIV-1 replication in human CD4+ CEM.NKR T-cells.
    Zhou T; Dang Y; Baker JJ; Zhou J; Zheng YH
    Retrovirology; 2012 Nov; 9():93. PubMed ID: 23134572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HIV-1 Vif protein mediates degradation of Vpr and reduces Vpr-induced cell cycle arrest.
    Wang J; Shackelford JM; Selliah N; Shivers DK; O'Neill E; Garcia JV; Muthumani K; Weiner D; Yu XF; Gabuzda D; Finkel TH
    DNA Cell Biol; 2008 May; 27(5):267-77. PubMed ID: 18462066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 Vpr mediates the depletion of the cellular repressor CTIP2 to counteract viral gene silencing.
    Forouzanfar F; Ali S; Wallet C; De Rovere M; Ducloy C; El Mekdad H; El Maassarani M; Aït-Ammar A; Van Assche J; Boutant E; Daouad F; Margottin-Goguet F; Moog C; Van Lint C; Schwartz C; Rohr O
    Sci Rep; 2019 Sep; 9(1):13154. PubMed ID: 31511615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of mobile chromatin-associated nuclear foci containing HIV-1 Vpr and VPRBP is critical for the induction of G2 cell cycle arrest.
    Belzile JP; Abrahamyan LG; Gérard FC; Rougeau N; Cohen EA
    PLoS Pathog; 2010 Sep; 6(9):e1001080. PubMed ID: 20824083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 Vpr Reprograms CLR4
    Yan J; Shun MC; Hao C; Zhang Y; Qian J; Hrecka K; DeLucia M; Monnie C; Ahn J; Skowronski J
    mBio; 2018 Oct; 9(5):. PubMed ID: 30352932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G2/M cell cycle arrest correlates with primate lentiviral Vpr interaction with the SLX4 complex.
    Berger G; Lawrence M; Hué S; Neil SJ
    J Virol; 2015 Jan; 89(1):230-40. PubMed ID: 25320300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.